Isoniazid

Tuberculosis

Volumn 88, Issue 2, 2008, Pages 112-116

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (COPPER CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING); BENZODIAZEPINE; CARBAMAZEPINE; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; ETHIONAMIDE; FATTY ACID SYNTHASE; GATIFLOXACIN; ISONIAZID; ISONIZIDA; KATG PROTEIN; LEVOFLOXACIN; PHENOBARBITAL; PHENYTOIN; PLUMBAGIN; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; SPARFLOXACIN; THEOPHYLLINE; TUBILYSIN; WARFARIN;

ACIDOSIS; ACUTE TOXICITY; AGRANULOCYTOSIS; ALCOHOL ABUSE; AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTIMICROBIAL ACTIVITY; ATROPHY; BACTERICIDAL ACTIVITY; BRAIN TOXICITY; CELL LINE; CONTROLLED STUDY; CONVULSION; DRUG ACTIVITY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG SOLUBILITY; DRUG TARGETING; DRUG TOLERABILITY; EOSINOPHILIA; EPIGASTRIC DISCOMFORT; FATIGUE; GENE MUTATION; GENE OVEREXPRESSION; GYNECOMASTIA; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; JAUNDICE; LD 50; LIVER DYSFUNCTION; LIVER TOXICITY; LUNG TUMOR; LYMPHADENOPATHY; MACROPHAGE; MALAISE; MALNUTRITION; MEMORY DISORDER; MESOTHELIOMA; MONOTHERAPY; MOUSE; MOUSE STRAIN; MYCOBACTERIUM BOVIS; MYCOBACTERIUM KANSASII; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NEUROPATHY; NONHUMAN; OPTIC NEURITIS; PARESTHESIA; PELLAGRA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSYCHOSIS; PYREXIA IDIOPATHICA; PYRIDOXINE DEFICIENCY; RASH; RAT; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; TUBERCULOSIS; URINE COLOR; VASCULITIS; VOMITING; WEAKNESS; WILD TYPE;

ANIMALS; ANTITUBERCULAR AGENTS; HUMANS; ISONIAZID; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43249131662     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1472-9792(08)70011-8     Document Type: Review

References (25)

1. Vilchèze C., et al. Transfer of a point mutation in MT inhA resolves the target for isoniazid. Nat Med 12 (2006) 1027-1029
2. Mdluli K., et al. Inhibition of a M. tuberculosis b-ketoacyl ACP synthase by isoniazid. Science 280 (1998) 1607-1610
3. Dessen A., et al. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267 (1995) 1638-1641
4. Rozwarski D., et al. Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrate. J Biol Chem 274 (1999) 15582-15589
5. Cohen-Gonsaud M., et al. Crystal structure of MabA from Mycobacterium tuberculosis, a reductase involved in long-chain fatty acid biosynthesis. J Mol Biol 320 (2002) 249-261
6. Vilchèze C., et al. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J Bacteriol 182 (2000) 4059-4067
7. Lee A., et al. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 45 (2001) 2157-2159
8. Rastogi N., et al. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 33 (1996) 167-175
9. Zhang Y. Isoniazid. In: Rom W., and Garay S. (Eds). Tuberculosis. 2nd edition (2003), Lippincott Williams & Wilkins, Philadelphia, PA 739-758
10. Jayaram R., et al. Isoniazid pharmacokinetics pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48 (2004) 2951-2957
11. Bultatovic V., et al. Oxidative stress increases susceptibility of Mycobacterium tuberculosis to isoniazid. Antimicrob Agents Chemother 46 (2002) 2765-2771
12. Bhusal Y., et al. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int J Antimicrob Agents 26 (2005) 292-297
13. Grosset J., and Ji B. Experimental chemotherapy of mycobacterial diseases. In: Gangadharan P., and Jenkins P. (Eds). Mycobacteria: II. Chemotherapy (1998), Chapman and Hall 51-97
14. Labana S., et al. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int J Antimicrob Agents 20 (2002) 301-304
15. Pandey R., et al. Poly (dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother 52 (2003) 981-986
16. Pandey R., et al. Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis. Int J Antimicrob Agents 23 (2004) 414-415
17. Grosset J., et al. Antagonism between isoniazid and the combination pyrazinamide rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36 (1992) 548-551
18. McIlleron H., et al. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 50 (2006) 1170-1177
19. Lake B., et al. Comparison of the effects of some CYP3A and other enzyme inducers on replicative DNA synthesis and cytochrome P450 isoforms in rat liver. Toxicology 131 (1998) 9-20
20. Deol P., et al. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob Agents Chemother 41 (1997) 1211-1214
21. Hearn M., and Cynamon M. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base. J Antimicrob Chemother 53 (2004) 185-191
22. Karthikeyan S. Isoniazid and rifampicin treatment on phospholipids and their subfractions in liver tissue of rabbits. Drug Chem Toxicol 28 (2005) 273-280
23. Sanders W., and Sanders C. Toxicity of antibacterial agents: mechanism of action on mammalian cells. Annu Rev Pharmacol Toxicol 19 (1979) 53-83
24. Self T., et al. Isoniazid drug and food interactions. Am J Med Sci 317 (1999) 304-311
25. Kinzig-Schippers M., et al. Should we use N- acetyltransferase type 2 genotyping to personalize isoniazid doses?. Antimicrob Agents Chemother 49 (2005) 1733-1738